Albrecht Stoehr

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

Christine Katlama, Roberto Esposito, José M. Gatell et al. · AIDS · 2007 · 180 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry

Giuseppe Boriani, Marco Proietti, Cécile Laroche et al. · EP Europace · 2017 · 166 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16

Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in <scp>HIV</scp>‐1‐infected treatment‐naïve patients in the <scp>ARTEMIS</scp> trial

Chloe Orkin, E DeJesus, Homayoon Khanlou et al. · HIV Medicine · 2012 · 158 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy

Helmut Albrecht, Christian Hoffmann, Olaf Degen et al. · AIDS · 1998 · 151 citations

Medicine, Infectious Diseases, Pharmacology +12